Flavoxate hydrochloride for urinary urgency after pelvic radiotherapy: comparison of 600 mg versus 1200 mg daily dosages.
This preliminary communication reports on a non-randomized pilot type trial of 34 females with urgency after pelvic radiotherapy who were treated with flavoxate hydrochloride for 4 weeks. A dosage of 600 mg/day was given to 21 patients and 1200 mg/day to 13 patients. Clinically, both regimens achieved comparable results. Urodynamically (first desire volume, bladder capacity and pressure at capacity) treatment with 1200 mg/day was significantly superior to 600 mg/day. Both schedules were equally well tolerated by patients and no treatment interruption occurred. A randomized double-blind trial comparing 600 and 1200 mg/day flavoxate hydrochloride is currently underway the results of which will be reported in due course.
Milani
R
R
Department of Obstetrics and Gynaecology, University of Milan, Italy.
Scalambrino
S
S
Carrera
S
S
Pezzoli
P
P
Ruffmann
R
R
D000328:Adult; D000368:Aged; D004305:Dose-Response Relationship, Drug; D005260:Female; D005419:Flavonoids / Q000627:therapeutic use*; D005422:Flavoxate / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008875:Middle Aged; D010388:Pelvis / Q000000981:diagnostic imaging*; D011859:Radiography; D014555:Urination Disorders / Q000188:drug therapy* / Q000209:etiology; D002583:Uterine Cervical Neoplasms / Q000532:radiotherapy
D005419:Flavonoids; D005422:Flavoxate